Angiotech Pharmaceuticals Inc - Statement of Ownership (SC 13G)
17 Dezember 2007 - 8:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
ANGIOTECH PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
034918102
(CUSIP Number)
December 6, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
o
|
|
Rule 13d-1(b)
|
|
|
þ
|
|
Rule 13d-1(c)
|
|
|
o
|
|
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out for a reporting persons initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for
the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to
the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Page 1 of 8
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
Highland Capital Management, L.P.
I.R.S. Identification Nos. of above persons (entities only).
75-2716725
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
4,473,800
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
4,473,800
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
4,473,800
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
5.3%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
PN/IA
|
Page 2 of 8
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
Strand Advisors, Inc.
I.R.S. Identification Nos. of above persons (entities only).
95-4440863
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
4,473,800
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
4,473,800
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
4,473,800
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
5.3%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
CO/HC
|
Page 3 of 8
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
James D. Dondero
I.R.S. Identification Nos. of above persons (entities only).
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
United States
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
4,473,800
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
4,473,800
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
4,473,800
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
5.3%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
IN/HC
|
Page 4 of 8
Item 1(a) Name of Issuer:
Angiotech Pharmaceuticals, Inc. (the
Issuer
).
Item 1(b) Address of Issuers Principal Executive Offices:
1618 Station Street
Vancouver, British Columbia
V6A 1B6
Item
2(a)
Name of Persons Filing:
This statement is filed by and on behalf of: (i) Highland Capital Management, L.P. (
Highland
Capital
); (ii) Strand Advisors, Inc. (
Strand
); and (iii) James D. Dondero (
Dondero
).
Highland Capital principally serves as an investment adviser and/or manager to other persons;
Highland Capital may be deemed to beneficially own shares owned and/or held by and/or for the
account of and/or benefit of other persons. Strand serves as the general partner of Highland
Capital; Strand may be deemed to beneficially own shares owned and/or held by and/or for the
account of and/or benefit of Highland Capital. Dondero is the President and a director of Strand;
Dondero may be deemed to beneficially own shares owned and/or held by and/or for the account of
and/or benefit of Strand.
Each of the reporting persons declares that neither the filing of this statement nor anything
herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or
13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this
statement.
Each of the reporting persons may be deemed to be a member of a group with respect to the
Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of
the reporting persons declares that neither the filing of this statement nor anything herein shall
be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the
Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other
person) as a partnership, limited partnership, syndicate, or other group for the purpose of
acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the
Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or
any securities of the Issuer.
Item 2(b) Address of Principal Business Office or, if non Residence:
The address of the principal business office of each of the reporting persons is Two Galleria
Tower, 13455 Noel Road, Suite 800, Dallas, Texas 75240.
Item 2(c) Citizenship:
See Item 4 of each cover page for the respective reporting persons.
Item 2(d) Title of Class of Securities:
Common Stock (the
Common Stock
).
Item 2(e) CUSIP Number:
034918102.
Item 3 Status of Persons Filing.
Not applicable.
Item 4 Ownership.
|
(a)
|
|
Amount Beneficially Owned:
|
|
|
|
|
See Item 9 of each cover page for the respective reporting persons.
|
|
|
(b)
|
|
Percent of Class:
|
Page 5 of 8
|
|
|
See Item 11 of each cover page for the respective reporting persons.
|
|
|
(c)
|
|
Number of shares as to which the person has:
|
|
(i)
|
|
Sole power to vote or to direct the vote:
|
|
|
|
|
See Item 5 of each cover page for the respective reporting persons.
|
|
|
(ii)
|
|
Shared power to vote or to direct the vote:
|
|
|
|
|
See Item 6 of each cover page for the respective reporting persons.
|
|
|
(iii)
|
|
Sole power to dispose or to direct the disposition of:
|
|
|
|
|
See Item 7 of each cover page for the respective reporting persons.
|
|
|
(iv)
|
|
Shared power to dispose or to direct the disposition of:
|
|
|
|
|
See Item 8 of each cover page for the respective reporting persons.
|
Item 5 Ownership of 5% or Less of a Class.
Not applicable.
Item 6 Ownership of More than 5% on Behalf of Another Person.
Highland Capital serves as an investment adviser and/or manager to other persons, including
Highland Crusader Offshore Partners, L.P. Highland Capital may be deemed to beneficially own shares
owned and/or held by and/or for the account and/or benefit of other persons, including Highland
Crusader Offshore Partners, L.P. The other persons, including Highland Crusader Offshore Partners,
L.P., may have the right to receive or the power to direct the receipt of dividends from, or the
proceeds from the sale of, shares owned and/or held by and/or for the account and/or benefit of
such persons.
|
|
|
Item 7
|
|
Identification and Classification of the Subsidiary Which Acquired the Security Being
Reported on by the Parent Holding Company or Control Person.
|
Not applicable.
Item 8 Identification and Classification of Members of the Group.
Not applicable.
Item 9 Notice of Dissolution of Group.
Not applicable.
Item 10 Certifications.
By signing below I certify that, to the best of my knowledge and belief, the securities
referred to above were not acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities and were not acquired and are
not held in connection with or as a participant in any transaction having that purpose or effect.
Page 6 of 8
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
Date: December 17, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highland Capital Management, L.P.
|
|
|
|
|
|
|
|
|
|
By:
|
|
Strand Advisors, Inc., its general partner
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James D. Dondero
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
|
|
Strand Advisors, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James D. Dondero
|
|
|
|
|
|
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
|
|
James D. Dondero
|
|
|
|
|
|
|
|
|
|
/s/ James D. Dondero
|
|
|
|
Page 7 of 8
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as
amended, the persons named below agree to the joint filing on behalf of each of them a Statement on
Schedule 13G (including amendments thereto) with regard to the Common Stock of Angiotech
Pharmaceuticals, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement
be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly
authorized, hereby execute this Joint Filing Agreement as of December 17, 2007.
|
|
|
|
|
|
|
Date: December 17, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highland Capital Management, L.P.
|
|
|
|
|
|
|
|
|
|
By:
|
|
Strand Advisors, Inc., its general partner
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James D. Dondero
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
|
|
Strand Advisors, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James D. Dondero
|
|
|
|
|
|
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
|
|
James D. Dondero
|
|
|
|
|
|
|
|
|
|
/s/ James D. Dondero
|
|
|
|
Page 8 of 8
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024